FDA Brief

Warning letters Drugs

FDA warning letter to

Richard J. Obiso, PhD dba Avila Herbals, LLC

High riskIssued Feb 4, 2022Posted Feb 15, 2022Center for Drug Evaluation and Research | CDER

FDA warns Avila Herbals and investigator over drug trial lacking required FDA application, ethics review, and consent.

What happened

FDA inspected the clinical site from July 12 to July 26, 2021, and reviewed Avila Herbals as sponsor and Dr. Obiso as clinical investigator. FDA found that a human study of an investigational drug began without an IND (an FDA application required before human testing), without review by an IRB (an ethics review board that meets FDA rules), without an IRB-approved written consent form, and without drug disposition records for subjects who received the drug.

What FDA found

  1. The company began a human study of an investigational drug without an IND (an FDA application required before human testing).

    21 CFR 312.20(a), 312.20(b), and 312.40(a)
  2. The investigator did not ensure that an IRB (an ethics review board that meets FDA rules) reviewed and approved the study before it began.

    21 CFR 312.66
  3. The investigator did not document informed consent with a written consent form approved by the IRB.

    21 CFR 312.60 and 21 CFR 50.27(a)
  4. The investigator did not keep drug disposition records showing dates, quantity, and use by subjects.

    21 CFR 312.62(a)

What FDA wants

FDA tells Dr. Obiso and Avila Herbals to respond in writing within 15 business days with the actions taken to prevent similar violations and to address the deficiencies; failure to do so may lead to regulatory action.

Who should pay attention

  • clinical investigators running early-phase drug studies
  • sponsors of botanical or other nonapproved product trials
  • IRBs and research compliance teams

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Nana Barseghian, M.D.

    FDA warns clinical investigator Nana Barseghian for enrolling high-body-mass-index subjects in drug trials despite protocol exclusion.

    High risk
  2. Mehran Michael Bahrami, M.D.

    FDA warns clinical investigator Dr. Mehran Michael Bahrami over protocol violations and missing records in investigational drug trials.

    High risk
  3. Daniel Fred Goodman, M.D./Goodman Eye Center

    FDA warns Dr. Daniel Fred Goodman/Goodman Eye Center over clinical drug study without required FDA application and missing consent/assent.

    High risk
  4. Smitha C. Reddy, M.D./ACRC Studies, LLC

    FDA warns Dr. Smitha Reddy over clinical trial protocol violations, including wrong drug given and broken blinding.

    High risk